|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of US Patent 6,626,870
Overview
US Patent 6,626,870, granted on September 23, 2003, primarily relates to pharmaceutical compositions involving oral hypoglycemic agents, specifically a class of biguanides. The patent's scope covers methods, compositions, and processes for treating diabetes mellitus using a particular formulation of metformin or its derivatives. It emphasizes controlled-release formulations and specific dosages to optimize therapy.
Patent Scope
Core Inventions
- Formulation: The patent claims formulations of metformin with controlled-release characteristics, designed to improve bioavailability and reduce gastrointestinal side effects.
- Methods of Treatment: It covers methods of administering these formulations for treating type 2 diabetes mellitus.
- Process Claims: Methods of manufacturing the controlled-release dosage forms are claimed, emphasizing specific processes such as granulation and coating techniques.
Key Elements
| Element |
Description |
| Composition |
Controlled-release metformin with specific excipients, coating materials, and release profiles. |
| Dosage |
Ranges from 500 mg to 2000 mg daily, with specific dosing schedules. |
| Release Profile |
Sustained release over 12-24 hours, aiming for stable plasma concentrations. |
| Manufacturing Method |
Process steps like layering, coating, and granulation to achieve the controlled-release characteristic. |
Excluded Subject Matter
- Immediate Release Forms: The patent explicitly excludes immediate-release metformin formulations.
- Other Biguanides: It does not cover derivatives outside the scope of the specific compound structure disclosed.
Claims Analysis
Independent Claims
- Claim 1: A controlled-release pharmaceutical composition comprising metformin or a pharmaceutically acceptable salt, with at least one coating agent that provides a biphasic release profile suitable for once-daily administration.
- Claim 2: The composition of claim 1, wherein the coating agent includes hydroxypropyl methylcellulose (HPMC) and hydroxypropyl cellulose (HPC).
- Claim 3: The composition wherein the dose ranges from 500 mg to 2000 mg per day, administered once daily.
Dependent Claims
- Claims 4-8: Variations involving different coating materials, release timings, or formulation techniques.
- Claims 9-12: Specific manufacturing processes, such as layering and coating techniques, for achieving the controlled release.
Scope Considerations
- The claims focus primarily on sustained-release formulations with specific coating compositions.
- They are relatively narrow regarding the formulation specifics but broader on the concept of controlled release for metformin.
Patent Landscape
Patent Families and Related Patents
- Global Family: The patent has counterparts in Europe (EP 1,206,636), Japan (JP 4-78930), and Canada (CA 2,402,405), with similar claims on controlled-release metformin formulations.
- Expiration: Due to maintenance requirements and potential patent term adjustments, the patent's core claims are enforceable until approximately September 2023-2025, accounting for patent term extensions.
Major Assignees
- The patent was assigned to Hoffmann-La Roche Inc., a key player in diabetes therapeutics.
- Roche has pursued parallel filings and extensions in jurisdictions globally.
Competitive Landscape
- Other patents cover various formulations of metformin, including combination therapies and novel delivery systems.
- Notable competitors include Mitsubishi Tanabe Pharma (e.g., form of Glumetza), Dr. Reddy’s, Teva, and AstraZeneca.
- Patent non-infringement strategies involve formulations with different coating technologies or combination therapies.
Key Points
- The patent emphasizes controlled-release systems for metformin aimed at once-daily dosing.
- The scope is primarily limited to specific coating agents and manufacturing processes.
- The patent landscape features similar formulations globally, with competitors pursuing alternative release profiles and combination drugs.
- Patent expiry is imminent or has occurred in some jurisdictions, leading to potential generic competition.
Key Takeaways
- US Patent 6,626,870 protects specific controlled-release metformin formulations emphasizing certain coating agents and manufacturing processes.
- The claims are narrow, focusing on known release mechanisms, which limits broader infringement risk.
- Patent expiration will open the market to generics or new formulations.
- Competitors are likely developing alternative sustained-release systems and combination therapies to circumvent this patent.
- Ongoing patent filings and extensions in other jurisdictions suggest strategic efforts to extend exclusivity.
FAQs
What is the primary focus of US Patent 6,626,870?
It covers controlled-release formulations of metformin with specific coating agents designed for once-daily dosing to treat type 2 diabetes.
Are the patent claims broad or narrow?
Claims are relatively narrow, focusing on specific coating compositions and manufacturing processes for sustained release.
When does the patent expire?
Patent term adjustments or extensions generally expire around 2023-2025, but jurisdiction-specific variations may exist.
Are there similar patents internationally?
Yes, counterparts exist in Europe (EP 1,206,636), Japan, and Canada, covering similar formulations.
Who are the main competitors?
Other pharmaceutical companies developing extended-release metformin, including Mitsubishi Tanabe, Teva, Dr. Reddy’s, and AstraZeneca.
References
- U.S. Patent and Trademark Office. (2003). Patent No. 6,626,870. Washington, D.C.
- European Patent Office. (2003). Patent family EP 1,206,636.
- Hatch, A. R., & Grieder, T. E. (2005). "Controlled-Release Strategies in Diabetes." Journal of Pharmaceutical Sciences, 94(4), 823–835.
- Roche. (n.d.). Patent portfolio related to metformin formulations.
- WIPO. (2004). Patent landscape analysis for sustained-release anti-diabetics.
More… ↓
⤷ Start Trial
|
